Effect of Artesunate on Haematological and Plasma Biochemical Parameters in Female Wistar Rats

K.O. Oyedeji* and A. Abiodun

Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria.
*Corresponding Author Email: sinaoyedeji@yahoo.com

https://dx.doi.org/10.13005/bpj/2706

This study was designed to investigate effect of artesunate on blood parameters in female rats. Ten female Wistar rats (130 – 150 g) were grouped into control and artesunate (1.43 mg/kg) – treated groups for blood assay. The artesunate was administered orally for 50 days. Hematological assay was carried out using hemocytometer, while biochemical assay was carried out using spectrophotometry. Mean +/- SEM and student's t-test at p<0.05 were determined. Artesunate (1.43 mg/kg) significantly reduced RBC, platelet and lymphocyte counts when compared to their controls. It also significantly decreased total protein, ALT and ALP values relative to their controls. However, it induced no significant changes in the PCV, Hb, TWBC, neutrophil, monocyte, eosinophil, MCV, MCHC, MCH, albumin, globulin, AST, BUN and creatinine values relative to their controls. Conclusively, it can be suggested that artesunate had both harmful and advantageous effects on blood parameters in female rats.

Keywords: Artesunate, Red blood cell, Lymphocyte, Total protein, Rats.

Artesunate is a drug used to cure malaria. It belongs to the artemisinin class of drugs. It is frequently administered in the form of combination therapy, for example artesunate combine with mefloquine. It is not used as a prophylaxis. Artesunate can be administered through intravenous injection, muscular injection as well as through oral and rectal administrations.

The drug is well tolerated when taken. It is preferred during the gestation period because of its high safety index, however contrary results were suggested by animal studies. It is also allowed to be taken by lactating mothers. Liu Xu invented this drug in 1977 and the World Health Organization has listed it as an essential medicine. Although artesunate is used mainly to treat malaria, evidence abounds that it could also has advantageous effects on infection due Schistosoma haematobium, but this has not been proven convincingly.

Its efficacy is similar to that of artemether when used to treat adults’ malaria induced by P. falciparum, however artesunate in combination with other drugs has superior advantages relative to artemether-based drugs, vis-à-vis, through uptake and through the routes of administration and probably could be more efficacious when treating serious malaria in children. Drugs that inactivate
hepatic enzyme CYP2A6 should not be taking alongside with artesunate, examples of such drugs are amiodarone, letrozole isoniazid e.t.c. The effect of artesunate on: rats’ kidneys toxicity, hemolysis and hypoglycemia induction in rats, developmental toxicities in rats and rabbits, hepatic histopathological changes in rats, embryotoxicity and toxicokinetics in rats, bone development toxicity in rats, reproductive function in female rats, stroke and other central nervous system therapeutic effects as well as on sub-chronic hemato-biochemical effects in rats have been reported.

But, as a result of limited information obtained concerning the activities of artesunate on blood parameters in female rats, hence, this research intends to bridge this gap.

**MATERIALS AND METHODS**

**Experimental Animals**

Ten female rodents of weight range 130 – 150 g raised in the Animal Holding of ABUAD were used in the current study. These rodents were accommodated in a conducive laboratory atmosphere with unlimited supply of feed and water; the acclimatization period was for two weeks. All animal experiments were carried out in accordance with ABUAD Ethical Committee (16/MHS01/015) on care and use of laboratory animals.

**Drug**

Artesunate (Green Energy, China) was purchased from Danax Pharmacy, Ibadan, Nigeria. Among these, artesunate (50 mg) was liquefied in 10 ml of distilled water to produce a concentration of 5.0 mg/ml. The dosage of the artesunate considered in this research was as recommended by the manufacturer.

Dosage: According to the manufacturer, for adult 2 tablets (each tablet weighed 50 mg) were to be given orally per day for a 70 kg adult.

Hence, 50 mg (x2) per day in a 70 kg adult. Therefore, dose to be used = 100/70 mg/kg = 1.43 mg/kg

**Experimental Design**

Ten matured female rats (five per group) used for this study received the following oral doses of artesunate and distilled water (control) for 50 days as follows:

- **Group A** rodents (control group) were given 0.5 ml/100 g of distilled water.
- **Group B** rodents were given 1.43 mg/kg of artesunate.

**Blood sample collection**

On day 51, blood samples were collected from the rodents and prepared as previously described.

**Haematological Parameters Determination**

The red blood cells (RBC) count, white blood cells (WBC) count, hemoglobin (Hb) concentration, packed cell volume (PCV), mean

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Artesunate (1.43 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCV (%)</td>
<td>51.50 ± 0.66</td>
<td>49.00 ± 0.15</td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>16.75 ± 0.34</td>
<td>15.90 ± 0.61</td>
</tr>
<tr>
<td>RBC (×10⁶/µL)</td>
<td>8.66 ± 0.04</td>
<td>7.98 ± 0.11*</td>
</tr>
<tr>
<td>TWBC (×10³/µL)</td>
<td>10.76 ± 0.36</td>
<td>4.24 ± 0.83</td>
</tr>
<tr>
<td>Platelet (×10⁵/µL)</td>
<td>1.34 ± 0.08</td>
<td>0.68 ± 0.07*</td>
</tr>
<tr>
<td>Lymphocyte (%)</td>
<td>74.25 ± 0.85</td>
<td>71.75 ± 0.83*</td>
</tr>
<tr>
<td>Neutrophil (%)</td>
<td>23.50 ± 0.89</td>
<td>25.25 ± 0.75</td>
</tr>
<tr>
<td>Monocyte (%)</td>
<td>1.75 ±0.31</td>
<td>1.50 ± 0.28</td>
</tr>
<tr>
<td>Eosinophil (%)</td>
<td>0.50 ±0.14</td>
<td>1.50 ± 0.36</td>
</tr>
<tr>
<td>MCV (FL)</td>
<td>59.46 ± 0.15</td>
<td>61.33 ± 0.12</td>
</tr>
<tr>
<td>MCHC (g/dL)</td>
<td>32.53 ± 0.24</td>
<td>32.47 ± 0.21</td>
</tr>
<tr>
<td>MCH (pg)</td>
<td>19.34 ± 0.14</td>
<td>19.91 ± 0.20</td>
</tr>
</tbody>
</table>

(n=5, *p<0.05)
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) were determined as previously reported 19.

**Biochemical Parameters Determination**

The total protein concentration, albumin concentration, globulin concentration, activities of plasma alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP), levels of creatinine and urea (BUN) were determined as previously reported 20.

**Statistical analysis**

Mean +/- SEM and student’s t-test at p<0.05 were determined.

**RESULTS**

From table 1, treatment of rodents with artesunate (1.43 mg/kg) induced significant (p<0.05) reductions in RBC, platelet and lymphocyte values relative to their controls. However, the table also revealed that treatment of rodents with artesunate (1.43 mg/kg) caused non-significant (p>0.05) changes in the other parameters as shown in the table.

From table 2, it was revealed that treatment of rodents with artesunate (1.43 mg/kg) caused significant (p<0.05) reductions in total protein, ALT and ALP values when compared to their controls. However, the table also revealed that treatment of rodents with artesunate (1.43 mg/kg) produced non-significant (p>0.05) changes in the other parameters as shown in the table.

**DISCUSSION**

The results have revealed that artesunate induced significant reduction in RBC value which suggests that the drug prevented erythropoietin secretion by the kidneys and caused decrease in oxygen binding capacity of blood with ultimate reduction in the quantity of oxygen transported to the tissues. Similar account was given by 21 in rodents treated with extract of *Plectranthus amboinicus*. This result was corroborated by the assertions of 22, 23.

Also, artesunate induced significant decrease in the platelet count which suggests that it prevented the haemostatic function of the body. Opposite result was given by 24 in rats treated with extract of *Fadogia agrestis*.

The drug caused insignificant change in TWBC value which suggests that it had no effect on resistance of the body to foreign pathogens. Opposite result was given by 25 in rodents treated with extract of *Viscum album*. This result was supported by the assertions of 26.

Artesunate produced significant decrease in lymphocyte count which could signify the body acquired immune suppression. Opposite result was given by 27 in rodents treated with isolated ergosterol.

Further, the drug produced non-significant change in eosinophil value which suggests the absence of anti-allergic and anti-parasitic infectious responses by the drug. Opposite result was given by 28 in rats and mice treated with extract of *Arctotis actotoides*.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Artesunate (1.43 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Protein (g %)</td>
<td>8.70 ± 0.07</td>
<td>8.33 ± 0.12*</td>
</tr>
<tr>
<td>Albumin (gm %)</td>
<td>3.40 ± 0.08</td>
<td>3.40 ± 0.14</td>
</tr>
<tr>
<td>Globulin (gm %)</td>
<td>5.30 ±0.04</td>
<td>4.93 ± 0.12</td>
</tr>
<tr>
<td>AST (µ/L)</td>
<td>45.00 ± 0.92</td>
<td>42.25 ± 1.03</td>
</tr>
<tr>
<td>ALT (µ/L)</td>
<td>33.25 ± 0.63</td>
<td>31.50 ± 0.74*</td>
</tr>
<tr>
<td>ALP (IU/L)</td>
<td>113.00 ± 1.93</td>
<td>110.50 ± 2.23*</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>17.53 ± 0.17</td>
<td>17.30 ± 0.13</td>
</tr>
<tr>
<td>Creatinine (µmol/L)</td>
<td>0.78 ± 0.02</td>
<td>0.73 ± 0.03</td>
</tr>
</tbody>
</table>

(n=5, *p<0.05)
Artesunate caused non-significant change in the neutrophil value which suggests the drug had no effect on the body response to pathogenic bacteria, viruses and other harmful agents. Opposite result was given by 29 in rodents treated with extract of Dennettia tripetala.

The drug induced non-significant change in the monocyte value which suggests that it lacked phagocytic function 30. Opposite result was given by 31 in hens fed with Saccharomyces cerevisiae.

Artesunate produced non-significant changes in MCV and MCH values which suggests the absence of effect on macrocytic anaemia induction. Similar account was given by 32 in rats treated with extract of Jatropha gossypifolia.

The drug produced insignificant change in the MCHC value which suggests absence of effect on hereditary spherocytosis induction. Similar account was given by 32 in rats treated with extract of Jatropha gossypifolia.

It has been reported that treatment of rats for 45 days with artesunate (2 mg/kg and 4 mg/kg) caused non-significant changes in hemoglobin, RBC, MCH, MCHC, lymphocytes and platelet values; but, the study also revealed that at 8.0 mg/kg, it caused significant (p<0.01) increase in PCV, MCH, TWBC, neutrophil and eosinophil values 18.

The plasma biochemical study results have revealed that artesunate caused significant reduction in total protein level which suggests that the drug inhibited blood buffering capacity and also decrease the colloidal osmotic pressure. Opposite result was given by 33 in rodents treated with extract of Euphorbia heterophylla. This result was validated by the assertion of 26.

In addition, artesunate produced significant reduction in ALT activity which could mean that it prevented the induction liver damage. Opposite result was given by 34 in rodents treated with extract of Moringa oleifera.

Artesunate caused significant decrease in ALP activity which suggests the inhibition of cholestasis. Opposite result was given by 35 in rats treated with losartan. This result was corroborated by the assertion of 36.

Artesunate induced non-significant change in the level of albumin which suggests that it had no effect on the levels of essential plasma components like amino acids, metals, bilirubin e.t.c. Contrary result was given by 37 in rats treated with extract of Enicostemma axillare.

Artesunate caused non-significant change in globulin level which suggests the lack of effect on both the natural and acquired immunity of the body. Similar account was given by 38 in rats treated with extracts of Portulaca oleracea.

The drug caused insignificant change in AST activity which could mean the lack of effect on induction of tissue necrosis. Opposite result was given by 39 in rodents treated with extract of Sida rhombifolia.

Artesunate produced non-significant change in creatinine level which suggests the absence of renal dysfunction. Opposite result was given by 40 Mucuna pruriens extract treated rats.

It has also been reported that treatment of rats for 45 days with artesunate (4 mg/kg and 8 mg/kg) caused significant (p<0.05–0.001) increase in SGOT, SGPT, ALP, TC, TG values; at 8.0 mg/kg, it also caused significant (p<0.05) increase in bilirubin level. However, at 2.0 mg/kg, 4.0 mg/kg and 8.0 mg/kg, it caused non-significant changes in total protein, albumin, creatinine and urea levels 18.

**CONCLUSION**

Conclusively, it can be suggested that artesunate had both harmful and advantageous effects on blood parameters in female Wistar rats.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge the Management of Afe Babalola University, Ado-Ekiti for supporting this work.

**Limitations of the study**

Scantiness of prior research studies on the topic: There were limited information obtained from literature concerning the activities of artesunate on blood parameters in female rats prior to the commencement of this study.

**Competing interest**

There is absence of conflicting interests in this study.
REFERENCES


